Zacks Research Issues Negative Forecast for Neogen Earnings

Neogen Co. (NASDAQ:NEOG) – Equities research analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Neogen in a report issued on Tuesday, January 28th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.12 for the quarter, down from their prior forecast of $0.14. The consensus estimate for Neogen’s current full-year earnings is $0.41 per share. Zacks Research also issued estimates for Neogen’s Q4 2025 earnings at $0.13 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.52 EPS.

Several other equities research analysts have also recently issued reports on the stock. Piper Sandler reiterated a “neutral” rating and set a $13.00 price target (down from $16.50) on shares of Neogen in a report on Tuesday, January 21st. Guggenheim started coverage on shares of Neogen in a research note on Thursday, December 19th. They issued a “buy” rating and a $15.00 target price for the company.

Neogen Trading Down 0.2 %

Neogen stock opened at $11.48 on Thursday. The stock has a 50-day moving average price of $12.52 and a 200 day moving average price of $14.71. Neogen has a 52 week low of $10.72 and a 52 week high of $18.58. The stock has a market cap of $2.49 billion, a PE ratio of -5.24 and a beta of 1.23. The company has a current ratio of 3.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.33.

Neogen (NASDAQ:NEOG) last announced its earnings results on Friday, January 10th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.12. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The firm had revenue of $231.30 million for the quarter, compared to analysts’ expectations of $227.16 million. During the same quarter in the prior year, the firm earned $0.11 EPS. Neogen’s quarterly revenue was up .7% on a year-over-year basis.

Insiders Place Their Bets

In other news, CFO David H. Naemura acquired 14,800 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was acquired at an average cost of $11.11 per share, for a total transaction of $164,428.00. Following the acquisition, the chief financial officer now directly owns 61,434 shares in the company, valued at approximately $682,531.74. This represents a 31.74 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO John Edward Adent bought 23,035 shares of Neogen stock in a transaction that occurred on Thursday, January 16th. The stock was purchased at an average price of $11.03 per share, for a total transaction of $254,076.05. Following the acquisition, the chief executive officer now directly owns 269,164 shares of the company’s stock, valued at $2,968,878.92. The trade was a 9.36 % increase in their position. The disclosure for this purchase can be found here. 1.13% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its position in shares of Neogen by 142.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock worth $33,000 after acquiring an additional 1,165 shares in the last quarter. Blue Trust Inc. increased its holdings in Neogen by 196.7% in the 4th quarter. Blue Trust Inc. now owns 3,368 shares of the company’s stock valued at $41,000 after purchasing an additional 2,233 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Neogen in the 3rd quarter valued at $66,000. KBC Group NV raised its position in Neogen by 39.1% in the fourth quarter. KBC Group NV now owns 8,464 shares of the company’s stock valued at $103,000 after purchasing an additional 2,379 shares during the period. Finally, Marco Investment Management LLC acquired a new position in shares of Neogen during the third quarter worth about $169,000. Hedge funds and other institutional investors own 96.73% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.